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The objective of this study is to demonstrate the effects of hydroxyurea in children with sickle 
cell disease at Madina Maternity and Children's Hospital and to evaluate its short term safety.  
 
Methods  
This was a retrospective review over two years period from 2004 – 2006. 
 The inclusion criteria were:  
1. Children with sickle cell disease who had three or more attacks of painful crisis per 
year  
2. Children with sickle cell disease who had two or more episodes of acute chest 
syndrome per year.  
The dose range of Hydroxyurea was 15 – 30 mg/kg/day. The clinical episodes and the 
laboratory investigations were monitored monthly.  
 
Results 
The total patients included initially were 14; 4 patients were excluded because of poor 
compliance to treatment.  
10 patients were eligible for the study. 6 were male and 4 were female.    8 patients were 
Saudi and 2 patients were non Saudis. The age range was   5 – 15 years.  
The attacks of painful crisis and acute chest syndrome were significantly reduced after 
Hydroxyurea treatment, also laboratory investigation showed significant increase in MCV 
and Hemoglobin F values after Hydroxyurea.  
Conclusion  
We conclude that Hydroxyurea is effective in children with sickle cell disease and had no 
major short term adverse effect.  However long terms follow up is required to evaluate long 
term adverse effect.  
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ickle cell disease is one of the most 
common hereditary disorders 
worldwide, the basic defect result from the 
substitution of valine for glutamic acid at 
the sixth position of E-globin1 . The sickle 
cell gene is prevalent in West Africa, Central 
Africa, The Mediterranean, the Middle East 
and certain parts of India.  
Sickle cell disease is a health problem in 
certain parts of Saudi Arabia in the Eastern, 
Western and the South West province.  
In Madina the estimated prevalence of sickle 
cell anemia (Hbss) is 0.01 and the carrier rate 
(HbAs) is 0.0872, and it is of severe Benin 
haplotype3, 4.  
One of the common hospital presentations 
of SCD in our institute are painful crisis and 
acute chest syndrome5, 6. Hydroxyurea (HU) 
is an antimetabolite agent , the mechanism 
by which it produce beneficial effects in 
patients with SCD is uncertain , however it 
is believed that it work by increasing the 
production of fetal haemoglobin in red 
blood cells , deceasing neutrophil , 
increasing water content of RBCs,  
increasing deformability of sickle cells and 
altering the adhesion of RBC to 
endothelium.  
There were various studies about the effect 
of HU in adult and children with SCD 
which showed significant reduction in the 
frequency of painful crisis, acute chest 
syndrome, hospitalization, and the need for 
blood transfusion7-9.  
The objective of this study is to demonstrate 
our experience with Hydroxyurea in 
children with sickle cell disease and to 
determine its beneficial effect and short term 
safety.  
 
Materials and Methods  
 
Children with severe sickle cell disease 
followed at Paediatric Haematology unit in 
Madina Maternity & Children's Hospital 
from February 2004 to February 2006, ages 5 
– 15 years were enrolled in the study. Severe 
disease was defined as follows:  
1. 3 or more painful crisis per year within 
two years before study entry. 
2. 2 or more episodes of acute chest 
syndrome (ACS) per year requiring 
hospital admission within the two years 
before study entry.  
Exclusion criteria included age less than 5 
years, poor compliance to medication, 
serum creatinine greater than 1.0 mg/dl, 
serum alanine transferase (ALT) more than 
twice the upper limit of normal. Before 
enrollment informed consent was obtained 
from the parents. The dose range of 
Hydroxyurea was 15 to 30 mg/kg/day. 
Patients initially started on 15 mg/kg orally 
as a single daily dose. The daily dose was 
increased by 5 mg/kg every 8 weeks in the 
absence of toxicity. Toxicity was defined as 
one or more of the following:  
1. Absolute neutrophil count ANC below 
2000 x 106/L  
2. A decrease in haemoglobin 
concentration by 20% from the steady 
state or Hb < 5 g/dl. 
3. A platelet count less than 80.000 x 106/L 
4. An ALT value greater than twice the 
upper limit of normal 
5. 50% increase from baseline in serum 
creatinine or value of more than 1.0 
mg/dl 
If toxicity occurs, HU was stopped for at 
least 1 week, once the toxicity resolved; 
treatment will then be resumed at a dose of 
2.5 mg/kg lower than the dose at which the 
toxicity occurred. An adverse event was 
defined as death or any life-threatening 
event.  
The patients were monitored monthly at 
outpatient's clinic visit interval histories, 
physical examination and laboratory results 
were recorded. Statistical analysis was 
performed with electronic web chi square 
calculator. P value was significant, if equal 
or less than 0.05.   
 
Results 
   
14 patients were enrolled in the study, 4 
patients were excluded because of poor 
compliance to HU. The total number of 
patients included in the study was 10 
S 
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patients; 6 male and 4 female. Eight patients 
were Saudi and 2 patients were non Saudis. 
Age range was 5 – 15 years with mean age 
of 12 years. Table 1 summaries the clinical 
and laboratory data at baseline and after 
Hydroxyurea treatment.  
The table shows that the number of painful 
crisis significantly decreased after 
Hydroxyurea treatment from 70 episodes to 
25; P value < 0.05 , while the number of ACS 
decreased from 8 to zero after Hydroxyurea 
with P value < 0.025. 90% of patient's Hb 
increased at least 1 gm/dl after HU 
treatment. 80% of patients showed 
significant increase of mean corpuscular 
volume (MCV) after HU therapy. 75% of 
those who had available result of HbF 
Hydroxyurea showed significant increase of 
HbF on HU therapy. The laboratory 
monitoring did not show evidence of 
haematological, hepatic or renal toxicities 




Table 1: Clinical and Laboratory Finding; baseline and on Hydroxurea treatment  
 Pre HU (2 years ) On HU ( 2 years) 
 N
um



























Platelet  X 10
3 
 N


















 Platelet X 10
3 
1 16 F 6 0 9.5 72 0 16 300 3 0 11.5 76 8.8 10 300 
2 13 M 5 0 8.8 76.1 12 10 450 2 0 8.6 79.6 25 12 400 
3 14 M 6 0 8.5 81 0 15 460 2 0 10.0 93 27 13 450 
4 12 F 11 0 8.8 62 30 16 316 4 0 10.1 71 25 14 300 
5 11 F 6 0 7.6 78 28.9 12 560 2 0 8.3 89 15 10 500 
6 15 F 25 0 8.0 79 0 20 450 11 0 9.0 87 NA 15 350 
7 8 M 6 0 7.0 68 0 10 360 1 0 7.8 72.7 NA 8 280 
8 5 M 1 2 8.0 80 5 10 200 0 0 8.94 82 20 10 220 
9 13 M 3 3 7.5 81 7.5 16 250 0 0 10.0 96 30 13 300 
10 11 M 1 3 8.8 72.5 12.9 20 400 0 0 9.9 80.9 18 15 350 
Total 
  70 8    25 0    
Hb  = Haemoglobin         MCV = mean corpuscular volume           HbF = Fetal haemoglobin        WBC= White 
blood count      
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Hydroxyurea had been approved by the 
United States of America Food and Drug 
Administration (FDA) for use in adults who 
suffer from severe painful crisis10. Since the 
multi-centers study of Hydroxyurea (MSH) 
in adult7, there were many studies in 
children demonstrating the beneficial effect 
of HU8, 9, 11. Hydroxyurea trial was started 
earlier in Saudi Arabia in adult by El Hazmi 
et al12.  
Recently, AL Jam'a et al reported a study on 
Hydroxyurea therapy in children older than 
10 years and adult in Saudi Arabia13. To the 
best of our knowledge there was no 
reported study in children younger than 10 
years in Saudi Arabia. Our study showed 
significant reduction in the number of 
painful crisis and acute chest syndrome, this 
result is consistent with beneficial effect of 
HU observed in other trials in adult and 
children7, 8, 9, 11. The youngest patient in our 
study was 5 years old; however others used 
HU in very young infant14 without serious 
short term complication.  
90% of our patients showed a rise of 
hemoglobin level after HU treatment, 75% 
of those who had available result of HbF 
level showed significant increase in HbF 
after HU treatment consistent with well 
established effect of HU in children and 
adult with SCD7, 8, 15, 16. It has been well 
established after extensive clinical and basic 
research that high HbF concentration 
reduces the severity of SCD by preventing 
the formation of hemoglobin S polymers. 
Mean corpuscular volume (MCV) increased 
after HU treatment in 80% of our patients 
similar to others7, 8. Increasing values of 
MCV were parallel to the rise in HbF 
concentration making the MCV a useful 
inexpensive surrogate for HbF during 
therapy.  
When MCV increase it improve sickle 
erythrocyte hydration which increase sickle 
cell deformability and that further 
contribute to the effect of HU in reducing 
frequency of painful crisis. Ten to 25% of 
SCD patients on HU treatment dose not had 
an increase in HbF level, perhaps because of  
Abnormal bone marrow, genetic factors, or 
variation in drug metabolism17, 18.  
No haematological , hepatic or renal 
toxicities were observed in our study, 
however other studies reported limited 
transient toxicities which were 
predominantly of mild neutropenia and 
minimal, if any, renal or hepatic toxicity 7,8,14 
. No adverse events were observed in our 
patients. 
Long term adverse effect of HU therapy is 
not yet known, but up to date no 
chromosomal breakage, mutation or 
carcinogenicity have been documented. In 
the adult MSH follow up study, no cases of 
leukemia have been observed in up to 9 
years of follow up19; also follow up of HU 
treatment in children for 7 years did not 
report any cases of malignancy20. Another 
recent report of long term effects in children 
showed no severe side effect or malignancy 
related to HU therapy for 10 years21. In 
French study 64 patients (age 5 – 45 years) 
with erythrocytosis caused by inoperable 
cyanotic congenital heart disease treated 
with Hydroxyurea for 2 to 15 years , 
reported no cases of malignancy or 
irreversible toxic effects22.  
Hydroxyurea also had a beneficial effect on 
preservation of splenic function. It has been 
reported that 47% of children had functional 
asplenia at age when about 80% would be 
expected to have asplenia by red cell pit 
counts after 2 years treatment with HU23. 
Splenic regeneration has been reported in 
two adults with sickle cell anemia treated 
with Hydroxyurea24. The adult MSH study 
suggests that HU should be considered for 
all patients with SCD, and the lack of 
significant short or long term toxicity in 
large cohort of children with SCD further 
support this recommendation.  
Hydroxyurea had no adverse effects on 
growth in children for up to 7 years 
treatment and puberty was achieved 
normally20.  
In conclusion, there is substantial evidence 
that Hydroxyurea is very beneficial and 
effective drug for children with severe SCD 
and we recommend for all children with 
severe sickle cell disease in the Kingdom of 
Saudi Arabia. There were no serious short or 
long term adverse effects up to date, but 
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